The second point: business scope
Point 3: Human insulin production company is a large pharmaceutical enterprise that produces Chinese and western medicines and biological medicines, a national key high-tech enterprise, and has become one of the considerable human insulin production bases in the world. The leading products are recombinant human insulin bulk drug (obtained the national GMP certificate), recombinant human insulin injection (Ganshulin R, Ganshulin N, Ganshushuang 30R, 40R, 50R, etc. ), Dongbao pen, etc. And "Tonghua" brand wine. At the same time, we independently developed three national-level new drugs with high technology and high added value: Teller rHuGM-CSF, Trzin rHuG-CSF and gene recombination. In addition, Qianlie 'an granules and 40/60 mixed recombinant human insulin injection are expected to obtain the production approval issued by the Food and Drug Administration on 20 1 1.
Fourth, the third generation insulin company transferred its 29.43% equity of Li Gan Pharmaceutical Company to a third party unanimously recognized by other shareholders of Li Gan Pharmaceutical Company at a price of not less than 400 million yuan. The company's original investment in Li Gan Pharmaceutical was 33.7 million yuan. After the transfer, the company will no longer hold its equity. Through this equity transfer, the company has obtained the patent authorization of insulin analogues, and can produce and sell insulin analogues in the next 42 months. Previously, the company signed patent licensing and proprietary technology licensing agreements with Li Gan Pharmaceutical and Tonghua Antaike Bio. Tonghua Antaike permits the Company to implement the patents and know-how of insulin analogues, but the Company shall not sell the intermediates, raw materials and preparations of insulin analogues obtained by implementing the patents and know-how of insulin analogues at home and abroad within 42 months from the date of signing this agreement. In the past, it was agreed that Li Gan Company could only produce and sell insulin analogues (the third generation) and the company could only produce and sell insulin (the second generation).
Point 5: Develop the market of county-level hospitals According to the goal of national medical reform, grass-roots hospitals, especially county-level hospitals, will be the most potential market for pharmaceutical sales in the future. 20 1 1 and in the next three years, the company will cooperate with the Endocrinology Society of Chinese Medical Association to educate doctors in grass-roots county hospitals about diabetes and rational use of insulin. The project will cover more than 3,000 doctors in county hospitals across the country. The company plans to achieve the goal of about 5,000 hospitals in 2065,438+065,438+0, and the sales revenue of Ganshulin will increase by more than 30%. 20111-February, there were 30 exhibitions of ganshulin pens in various places, covering nearly 5000 endocrinologists in hospitals at all levels in China.
Point 6: In February 20 10, the recombinant human insulin expansion company increased its capital to Beijing Dongbao Pharmaceutical Company, a wholly-owned subsidiary, so that the registered capital increased from 100000 yuan to100000 yuan. A new insulin preparation construction project meeting the requirements of FDA of the United States and EMEA cGMP of the European Union will be built, with an annual production scale of1200,000 tablets and a construction period of two years. The annual production scale of the company's high-quality recombinant human insulin raw materials has been expanded from 200 kg to 3000 kg, and the series products of Ganshulin R, Ganshulin N, Ganshulin 30R and Ganshulin 50R have been put on the market. Since 2000, recombinant human insulin products have been exported to Pakistan.
Seventh: Only two companies in the world have a full range of insulin products, including tonghua dongbao. Moreover, in the global insulin market, only three companies, tonghua dongbao, Novo Nordisk and Eli Lilly, USA, mass-produce the second-generation insulin. Under the global market competition pattern of oligopoly, the product quality of the three companies is indistinguishable, and the comprehensive production cost of tonghua dongbao is the lowest. Compared with the expensive insulin of multinational giants, Dongbao insulin can reduce the government's medical insurance expenditure on insulin, and will become a powerful competitor for multinational giants' market share in developing countries in the future.
Point 8: Concept of biopharmaceuticals Xiamen Tebao Bioengineering Co., Ltd. (registered capital is 476.5438+10,000 yuan, and the company holds 40.766% of the shares) is a high-tech enterprise engaged in research and development, production and sales of genetic engineering drugs and bioengineering products. Independent research and development of two national-level new drugs, Teli and Trzin, has formed an industrial scale with an annual output of 500 grams of injections and 500,000 freeze-dried powder injections. In addition, the company achieved a net profit of 9.87 million yuan in 20 10.
Ninth point: The equity investment company initially invested 65.438+0.27 billion yuan in TongPortugal shares (600.365), accounting for 65.438+0.3.65% of its total share capital. As of February, 2065.438+00,654.38+0, the book value at the end of the period was 35.55 million yuan. During the period of 20 10, the company sold10.96 million shares, and the company still holds 3 million shares.
Point 10: The theme of share reform Dongbao Industrial Group promises that the original non-tradable shares in tonghua dongbao will not be listed and traded within 60 months from the date of obtaining the right of listing and circulation (June 7, 2006). Within 24 months after the above lock-up period expires, the price listed for sale through the stock exchange shall not be lower than that of 6 yuan.